Indoco Remedies · NSE: INDOCO · BSE: 532612
Q4 FY26 results · Jan–Mar 2026
Indoco Remedies reported revenue from operations of ₹475.61 crore (up 21.9% from Q4 FY25) and net loss of ₹23.68 crore for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 475.61 | 390.21 | +21.9% | 445.36 | +6.8% |
| Other income | (0.04) | 2.02 | Turned loss | 0.98 | Turned loss |
| Total income | 475.57 | 392.23 | +21.2% | 446.34 | +6.5% |
| Profit before tax | (25.00) | (45.52) | Loss narrowed | (31.31) | Loss narrowed |
| Net profit for the period | (23.68) | (41.34) | Loss narrowed | (29.45) | Loss narrowed |
| Attributable to shareholders of the company | (21.64) | (40.39) | Loss narrowed | (29.79) | Loss narrowed |
| EPS, basic (₹) | (2.57) | (4.48) | Loss narrowed | (3.20) | Loss narrowed |
| Net margin (%) | -5.0 | -10.6 | -6.6 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 449.13 | 347.25 | +29.3% | 400.51 | +12.1% |
| Other income | 10.35 | 6.50 | +59.2% | 7.17 | +44.4% |
| Total income | 459.48 | 353.75 | +29.9% | 407.68 | +12.7% |
| Profit before tax | 27.62 | (30.90) | Turned profit | (20.45) | Turned profit |
| Net profit for the period | 27.35 | (26.24) | Turned profit | (20.00) | Turned profit |
| EPS, basic (₹) | 2.96 | (2.85) | Turned profit | (2.17) | Turned profit |
| Net margin (%) | 6.1 | -7.6 | -5.0 |
Consolidated
- Filed with BSE
- 07 May 2026, 20:24 IST
- Board meeting
- 07 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 May 2026, 20:24 IST
- Board meeting
- 07 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE